The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.
Berger
Timothy G
TG
Department of Dermatology, University of California, San Francisco, California, USA. vlebrun@aad.org
Duvic
Madeleine
M
Van Voorhees
Abby S
AS
VanBeek
Marta J
MJ
Frieden
Ilona J
IJ
D000287:Administration, Topical; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D009369:Neoplasms / Q000139:chemically induced*; D012307:Risk Factors; D012449:Safety; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus